focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 85.00
Bid: 84.40
Ask: 84.85
Change: 2.15 (2.60%)
Spread: 0.45 (0.533%)
Open: 83.50
High: 85.00
Low: 82.40
Prev. Close: 82.85
DOCS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chief Brand Officer Appointment

16 Nov 2023 07:00

RNS Number : 6029T
Dr. Martens PLC
16 November 2023
 

16 November 2023

Dr. Martens plc

Creation of Chief Brand Officer role

Ije Nwokorie appointed into new role and will step down as Non-Executive Director as a result

 

Dr. Martens plc announces that Non-Executive Director Ije Nwokorie will join as Chief Brand Officer from 1st February 2024. On appointment into this role, Ije will cease to be a member of the Board and will step down as a member of the Audit and Risk, Nomination and Disclosure committees.

The newly-created role of Chief Brand Officer will be a key member of the global leadership team, reporting into Kenny Wilson, CEO, overseeing the Global Marketing, Product and Strategy functions. The Chief Brand Officer will be responsible for setting the overall brand strategy, vision and direction for the next phase of Dr. Martens' growth.

Ije will join Dr. Martens as Chief Brand Officer from Apple Inc, where he has been Senior Director, Apple Retail since January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of non-profit organisation charity: water UK.

Paul Mason, Chair, said "Ije has been a tremendous Non-Executive Director since he joined the Board in January 2021. He has deep insight and understanding of brands and has extensive global DTC experience. I am delighted that he'll be joining the leadership team as Chief Brand Officer, a role for which he is perfectly suited."

Kenny Wilson, CEO, said "Ije is a visionary brand storyteller and this, along with his infectious passion for Dr. Martens, makes him the ideal person to lead the next era of our brand development. I am delighted that he will be joining my team in a permanent full-time position of Chief Brand Officer, which will be a crucial role to enable us to become a £2bn revenue brand."

Ije Nwokorie said "I've always loved Dr. Martens and it's been a real privilege getting to know the brand from the inside as a Non-Executive Director. Dr. Martens is defined by its rebellious, authentic and creative nature, all of which makes me really excited to be joining Kenny and the team early in the new year and to get to work."

 

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations Bethany.Barnes@drmartens.com +44 7825 187465

Beth Callum, Senior Investor Relations Analyst Beth.Callum@drmartens.com +44 203 995 2644

 

Press

H/Advisors Maitland +44 207 379 5151

Clinton Manning +44 7711 972662

 

Gill Hammond, Director of Communications +44 7384 214248

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNBLBDBGUBDGXU
Date   Source Headline
1st Jul 20219:00 amRNSAnnual Financial Report
25th Jun 202112:46 pmRNSHolding(s) in Company
23rd Jun 20216:19 pmRNSHolding(s) in Company
21st Jun 202110:39 amRNSDirector/PDMR Shareholding
18th Jun 20213:16 pmRNSHolding(s) in Company
17th Jun 20217:00 amRNSFinal Results
16th Jun 20215:40 pmRNSHolding(s) in Company
13th Apr 20217:00 amRNSAppointment of Joint Corporate Brokers
10th Feb 20219:00 amRNSDirector/PDMR Shareholding
9th Feb 20211:41 pmRNSHolding(s) in Company
5th Feb 202112:52 pmRNSHolding(s) in Company
5th Feb 20219:20 amRNSExercise of Over-allotment Option
4th Feb 20215:20 pmRNSHolding(s) in Company
3rd Feb 20218:00 amRNSTotal Voting Rights
3rd Feb 20218:00 amRNSAdmission to Trading on the London Stock Exchange
1st Feb 20214:53 pmRNSDirector/PDMR Shareholding
29th Jan 202111:18 amRNSStabilisation Notice
29th Jan 202110:48 amRNSApproval and Publication of Prospectus
29th Jan 20217:00 amRNSAnnouncement of Offer Price

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.